v3.26.1
Collaboration and license agreements (Tables)
 6 Months Ended
Jun. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of allocation of transaction price
The following table summarizes the allocation of the total transaction price to the identified performance obligations under the arrangement, and the amount of the transaction price unsatisfied as of June 30, 2026 (in thousands):
Transaction
Price
Allocated		Transaction
Price
Unsatisfied
Performance obligations:
Research and development targets$21,272 $3,975 
Option rights2,460 2,460 
Total$23,732 $6,435 
Schedule of revenue from collaboration agreements
Revenue from collaboration agreements for the three and six months ended June 30, 2026 and 2025 in the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Revenue from collaboration agreements:
Roche DAC Agreement$2,666 $— $2,666 $— 
MKDG Agreement1,833 3,428 3,595 6,581 
Betta Agreements15 54 20 514 
Roche Agreement2,127 1,932 4,512 4,428 
Biogen Agreement— — 2,000 — 
Merck Agreement— 1,049 — 2,178 
Total revenue from collaboration agreements$6,641 $6,463 $12,793 $13,701 
Schedule of financial information related to collaboration and license agreements
Financial information related to the collaboration and license agreements consisted of the following in the Company’s condensed consolidated balance sheet as of June 30, 2026 (in thousands):
Accounts
Receivable		Deferred Revenue,
Current		Deferred Revenue,
Net of Current		Deferred Revenue,
Total
Supplemental information:
Roche DAC Agreement$— $17,334 $— $17,334 
MKDG Agreement953 2,153 — 2,153 
Betta Agreements5 989 13,714 14,703 
Roche Agreement376 6,185 — 6,185 
Biogen Agreement— — — — 
Total$1,334 $26,661 $13,714 $40,375 
Financial information related to the collaboration and license agreements consisted of the following in the Company’s condensed consolidated balance sheet as of December 31, 2025 (in thousands):
Accounts
Receivable		Deferred Revenue,
Current		Deferred Revenue,
Net of Current		Deferred Revenue,
Total
Supplemental information:
MKDG Agreement$1,892 $3,913 $— $3,913 
Betta Agreements9 531 14,194 14,725 
Roche Agreement500 8,049 1,647 9,696 
Total$2,401 $12,493 $15,841 $28,334 
Schedule of supplemental financial information related to collaboration and license agreements
Supplemental financial information related to the collaboration and license agreements for the three and six months ended June 30, 2026 and 2025 is (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Revenue recognized that was included in the contract liability at the beginning of the period$2,820 $6,512 $6,560 $11,821